Literature DB >> 21225438

Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus.

Patrick Michael Shaughn O'Brien1, Torbjorn Bäckström, Candace Brown, Lorraine Dennerstein, Jean Endicott, C Neill Epperson, Elias Eriksson, Ellen Freeman, Uriel Halbreich, Khaled M K Ismail, Nicholas Panay, Teri Pearlstein, Andrea Rapkin, Robert Reid, Peter Schmidt, Meir Steiner, John Studd, Kimberley Yonkers.   

Abstract

Premenstrual disorders (PMD) are characterised by a cluster of somatic and psychological symptoms of varying severity that occur during the luteal phase of the menstrual cycle and resolve during menses (Freeman and Sondheimer, Prim Care Companion J Clin Psychiatry 5:30-39, 2003; Halbreich, Gynecol Endocrinol 19:320-334, 2004). Although PMD have been widely recognised for many decades, their precise cause is still unknown and there are no definitive, universally accepted diagnostic criteria. To consider this issue, an international multidisciplinary group of experts met at a face-to-face consensus meeting to review current definitions and diagnostic criteria for PMD. This was followed by extensive correspondence. The consensus group formally became established as the International Society for Premenstrual Disorders (ISPMD). The inaugural meeting of the ISPMD was held in Montreal in September 2008. The primary aim was to provide a unified approach for the diagnostic criteria of PMD, their quantification and guidelines on clinical trial design. This report summarises their recommendations. It is hoped that the criteria proposed here will inform discussions of the next edition of the World Health Organisation's International Classification of Diseases (ICD-11), and the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) criteria that are currently under consideration. It is also hoped that the proposed definitions and guidelines could be used by all clinicians and investigators to provide a consistent approach to the diagnosis and treatment of PMD and to aid scientific and clinical research in this field.

Entities:  

Mesh:

Year:  2011        PMID: 21225438      PMCID: PMC4134928          DOI: 10.1007/s00737-010-0201-3

Source DB:  PubMed          Journal:  Arch Womens Ment Health        ISSN: 1434-1816            Impact factor:   3.633


  21 in total

1.  Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives.

Authors:  H Sveindóttir; T Bäckström
Journal:  Acta Obstet Gynecol Scand       Date:  2000-05       Impact factor: 3.636

Review 2.  The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis.

Authors:  Katrina M Wyatt; Paul W Dimmock; Khaled M K Ismail; Peter W Jones; P M Shaughn O'Brien
Journal:  BJOG       Date:  2004-06       Impact factor: 6.531

3.  Daily Record of Severity of Problems (DRSP): reliability and validity.

Authors:  J Endicott; J Nee; W Harrison
Journal:  Arch Womens Ment Health       Date:  2005-09-20       Impact factor: 3.633

4.  Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects.

Authors:  D R Rubinow; M C Hoban; G N Grover; D S Galloway; P Roy-Byrne; R Andersen; G R Merriam
Journal:  Am J Obstet Gynecol       Date:  1988-01       Impact factor: 8.661

5.  Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome.

Authors:  T Bäckström; D Sanders; R Leask; D Davidson; P Warner; J Bancroft
Journal:  Psychosom Med       Date:  1983-12       Impact factor: 4.312

6.  The measurement of premenstrual mood symptoms.

Authors:  M Steiner; D L Streiner; S Steinberg; D Stewart; D Carter; C Berger; R Reid; D Grover
Journal:  J Affect Disord       Date:  1999-06       Impact factor: 4.839

7.  Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.

Authors:  P J Schmidt; L K Nieman; M A Danaceau; L F Adams; D R Rubinow
Journal:  N Engl J Med       Date:  1998-01-22       Impact factor: 91.245

8.  Premenstrual Dysphoric Disorder: Recognition and Treatment.

Authors:  Ellen W. Freeman; Steven J. Sondheimer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02

9.  Lasting response to ovariectomy in severe intractable premenstrual syndrome.

Authors:  P Casson; P M Hahn; D A Van Vugt; R L Reid
Journal:  Am J Obstet Gynecol       Date:  1990-01       Impact factor: 8.661

10.  Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes.

Authors:  U Halbreich; N Rojansky; S Palter
Journal:  Fertil Steril       Date:  1991-12       Impact factor: 7.329

View more
  48 in total

Review 1.  [Prevalence of Menstrual Disorders according to Body Mass Index and Lifestyle Factors: The National Health Insurance Service-National Health Screening Cohort in Korea, 2009~2016].

Authors:  SoMi Park; Tae Woong Yoon; Dae Ryong Kang; ChaeWeon Chung
Journal:  J Korean Acad Nurs       Date:  2020-06       Impact factor: 0.984

2.  Variance in Mood Symptoms Across Menstrual Cycles: Implications for Premenstrual Dysphoric Disorder.

Authors:  Tierney K Lorenz; Amanda N Gesselman; Virginia J Vitzthum
Journal:  Womens Reprod Health (Phila)       Date:  2017-07-10

3.  Low-dose acetazolamide in the treatment of premenstrual dysphoric disorder: a case series.

Authors:  Gabriele Sani; Georgios D Kotzalidis; Isabella Panaccione; Alessio Simonetti; Lavinia De Chiara; Antonio Del Casale; Elisa Ambrosi; Flavia Napoletano; Delfina Janiri; Emanuela Danese; Nicoletta Girardi; Chiara Rapinesi; Daniele Serata; Giovanni Manfredi; Alexia E Koukopoulos; Gloria Angeletti; Ferdinando Nicoletti; Paolo Girardi
Journal:  Psychiatry Investig       Date:  2014-01-21       Impact factor: 2.505

4.  The Influence of Cyclic Hormonal Contraception on Expression of Premenstrual Syndrome.

Authors:  Kimberly A Yonkers; Brianna Cameron; Ralitza Gueorguieva; Margaret Altemus; Susan G Kornstein
Journal:  J Womens Health (Larchmt)       Date:  2016-11-17       Impact factor: 2.681

Review 5.  Premenstrual Dysphoric Disorder: Epidemiology and Treatment.

Authors:  Liisa Hantsoo; C Neill Epperson
Journal:  Curr Psychiatry Rep       Date:  2015-11       Impact factor: 5.285

6.  ISPMD consensus on the management of premenstrual disorders.

Authors:  Tracy Nevatte; Patrick Michael Shaughn O'Brien; Torbjorn Bäckström; Candace Brown; Lorraine Dennerstein; Jean Endicott; C Neill Epperson; Elias Eriksson; Ellen W Freeman; Uriel Halbreich; Khalid Ismail; Nicholas Panay; Teri Pearlstein; Andrea Rapkin; Robert Reid; David Rubinow; Peter Schmidt; Meir Steiner; John Studd; Inger Sundström-Poromaa; Kimberly Yonkers
Journal:  Arch Womens Ment Health       Date:  2013-04-27       Impact factor: 3.633

Review 7.  Selective serotonin reuptake inhibitors for premenstrual syndrome.

Authors:  Jane Marjoribanks; Julie Brown; Patrick Michael Shaughn O'Brien; Katrina Wyatt
Journal:  Cochrane Database Syst Rev       Date:  2013-06-07

8.  Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study.

Authors:  Erika Timby; Torbjörn Bäckström; Sigrid Nyberg; Hans Stenlund; Anna-Carin N Wihlbäck; Marie Bixo
Journal:  Psychopharmacology (Berl)       Date:  2016-03-10       Impact factor: 4.530

Review 9.  Premenstrual dysphoric disorder and severe premenstrual syndrome in adolescents.

Authors:  Andrea J Rapkin; Judith A Mikacich
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

10.  Association of Premenstrual Syndrome with Blood Pressure in Young Adult Women.

Authors:  Elizabeth R Bertone-Johnson; Serena C Houghton; Brian W Whitcomb; Lynnette L Sievert; Sofija E Zagarins; Alayne G Ronnenberg
Journal:  J Womens Health (Larchmt)       Date:  2016-07-15       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.